Results 171 to 180 of about 1,726 (212)

Photopheresis (extracorporeal photochemotherapy)

Photochemical & Photobiological Sciences, 2012
Photopheresis is a form of phototherapy where specialized equipment is used to isolate a leukocyte fraction from the peripheral blood which is then exposed to photoactivated 8-methoxypsoralen and reinfused into the patient. At the time of its invention the treatment was conceptually based on the hypothesis of T cell vaccination, i.e. the observation in
Franz, Trautinger, Ulrike, Just, Robert, Knobler   +2 more
openaire   +2 more sources

Extracorporeal photochemotherapy in mycosis fungoides

Transfusion Clinique et Biologique, 2017
Extracorporeal photo-chemotherapy (ECP, photopheresis) is an approved treatment modality for mycosis fungoides (MF). Our aim is to present our ECP data for MF.We retrospectively evaluated 50 MF patients who received ECP for clinical activity, toxicity, and response and outcome rates, and we compared these with combination therapies.The overall response
E. Atilla, P.A. Atilla, S.C. Bozdag, M.K. Yuksel, S.K. Toprak, P. Topcuoglu, B.N. Akay, H. Sanli, H. Akan, T. Demirer, M. Beksac, O. Arslan, M. Ozcan, G. Gurman, O. Ilhan   +14 more
openaire   +2 more sources

Extracorporeal photochemotherapy

Journal of Dermatological Science, 2009
Although extracorporeal photochemotherapy (ECP) is reported to be effective for a wide variety of diseases, such as cutaneous T cell lymphoma, autoimmune diseases, organ graft rejection, and graft versus host disease, its mechanism of action remains unclear. The basis of extracorporeal photopheresis is the reinfusion of leukocytes previously exposed to
openaire   +2 more sources

EXTRACORPOREAL PHOTOCHEMOTHERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS

International Journal of Dermatology, 1993
Abstract Background. Extracorporeal photochemotherapy, an immune‐modulating form of therapy, has been shown to be effective in the treatment of autoimmune diseases. We evaluated the effects of extracorporeal photochemotherapy in the treatment of patients with progressive systemic sclerosis (pss). Methods.
F X, Di Spaltro, C, Cottrill, C, Cahill, E, Degnan, G J, Mulford, D, Scarborough, A J, Franks, A S, Klainer, E, Bisaccia   +8 more
openaire   +2 more sources

Dosage guidelines: extracorporeal photochemotherapy (photopheresis)

Archives of dermatology, 1990
To the Editor.— Extracorporeal photochemotherapy (photopheresis) has been approved for the treatment of cutaneous T-cell lymphoma. During the clinical trial that documented the effectiveness of this therapy, 1 patients were treated with a minimum of 0.6 mg/kg crystalline 8-methoxypsoralen (8-MOP).
P W, Heald, M I, Perez, F P, Gasparro
openaire   +3 more sources

Extracorporeal photochemotherapy – the Columbia Presbyterian experience

Photodermatology, Photoimmunology & Photomedicine, 2002
Background:Cutaneous T Cell Lymphoma (CTCL) is a lymphoma of skin homing usually CD4  +  lymphocytes. There are numerous treatments available both for the early as well as the more advanced stages of the disease. Extracorporeal photochemotherapy is a well‐accepted form of treating CTCL.
Elizabeth, Knobler, Ingrid, Warmuth, Carolyn, Cocco, Barbara, Miller, Julian, Mackay   +4 more
openaire   +2 more sources

[Extracorporeal photochemotherapy].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2010
Photopheresis or extracorporeal photochemotherapy (ECP) is a cellular therapy which combines a leukapheresis followed by ex vivo treatment using psoralen and ultraviolet A irradiation before reinfusion into the patient. Its mechanisms of action remain unclear and selective photodestruction of leukocytes cannot explain the long-lasting immunomodulatory ...
Viguier, M., Pouthier, F., Tiberghien, Pierre, Aubin, François   +3 more
openaire   +2 more sources

Extracorporeal Photochemotherapy ‐ Present and Future

Vox Sanguinis, 2000
Extracorporeal photochemotherapy (ECP) was introduced by Edelson and co‐workers in 1985. Since then the therapy, though still controversial in specific indications, has received wide acceptance and is presently been used in over 160 centers in Europe and the U.S.A. for a number of important dermatological and non‐dermatological indications.
openaire   +2 more sources